DoD tests AI models that make it easy to switch from vendors like Palantir
Mark S. Schroeder, Executive Vice President, President of Diagnostics, and Chief Operating Officer at Labcorp Holdings Inc. (NYSE:LH), recently executed a significant stock transaction. According to a recent SEC filing, Schroeder sold 5,339 shares of Labcorp common stock on February 28, 2025, at an average price of $249.23 per share, totaling approximately $1.33 million. The transaction comes as Labcorp, currently valued at $21.3 billion, trades near its 52-week high of $258.59. InvestingPro data shows the stock has gained over 17% in the past year, with notably low price volatility.
In addition to this sale, Schroeder acquired 3,903 shares through the exercise of stock options at a price of $131.43 per share, resulting in a total acquisition value of approximately $512,971. Following these transactions, Schroeder holds 4,960 shares of Labcorp stock.
These trades were conducted under a pre-established Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks, typically to avoid any accusations of insider trading.
In other recent news, Laboratory Corporation of America (LabCorp) has been the focus of several analyst upgrades and strategic developments. Citi analysts upgraded LabCorp’s stock rating from Neutral to Buy, increasing the price target to $300, citing strong utilization rates in the Labs industry and the strategic acquisition of Invitae (OTC:NVTAQ). Truist Securities also raised LabCorp’s price target to $285 while maintaining a Buy rating, following strong fourth-quarter performance and promising guidance for 2025. Jefferies analyst Tycho Peterson increased the price target to $290, highlighting LabCorp’s robust financial results and strong free cash flow, despite some margin impacts from transient items.
LabCorp’s recent release of the Labcorp Plasma CompleteTM, a liquid biopsy test for advanced cancer care, marks a significant advancement in its oncology portfolio. This test provides comprehensive genomic profiling, which can aid oncologists in personalizing treatment plans for patients with advanced solid tumors. The test is validated in LabCorp’s CAP-accredited and CLIA-certified laboratory and boasts a high specificity rate.
Meanwhile, Immutep (NASDAQ:IMMP) Limited reported its half-year financial results in a recent SEC filing. While specific financial details were not disclosed in the summary, the full report is available in the filing’s exhibit section, offering insights into the company’s financial performance. Investors are encouraged to review the comprehensive report for detailed information on Immutep’s revenue, expenses, and profit margins.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.